| Similar Articles |
|---|
 |
American Family Physician
December 15, 2005
Hadley & Gaarder |
Treatment of Irritable Bowel Syndrome Irritable bowel syndrome affects 10% to 15% of the U.S. population to some degree. Diagnosis is based on clinical signs and symptoms that include abdominal pain, bloating, constipation, and diarrhea.   |
American Family Physician
October 15, 2006
Jarvis & Golding |
Lubiprostone (Amitiza) for Chronic Idiopathic Constipation Although bulk or osmotic laxatives are less expensive first options for treating patients with chronic idiopathic constipation, lubiprostone is an alternative for those who do not tolerate or respond to these agents, or in patients older than 65 years in whom tegaserod use is not recommended. |
American Family Physician
November 15, 2002
Viera et al. |
Management of Irritable Bowel Syndrome Irritable bowel syndrome is the most common functional disorder of the gastrointestinal tract and is frequently treated by family physicians. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Nurse Practitioner
May 2012
Diana L. Wadlund |
Meeting the challenge of IBS IBS is the best studied, most common functional GI disorder, and is often characterized by debilitating symptoms without any pathologic findings. The predominant symptoms of IBS are abdominal pain and an alteration in bowel habits with an absence of organic pathology. |
Nursing
February 2009
Daniel A. Hussar |
New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension. |
Pharmaceutical Executive
May 1, 2006
Madison, Chan & Seeger |
Making the Link The FDA recognizes that a new drug standard must evolve -- one of routine, proactive safety surveillance. But post-marketing safety studies are too slow. Here's how pharmaceuticals are using claims databases to solve the problem. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
Wired
August 24, 2009
Steve Silberman |
Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology. |
American Family Physician
May 15, 2003
Holten & Wetherington |
Problem-Oriented Diagnosis Diagnosing the patient with abdominal pain and altered bowel habits: is it irritable bowel syndrome? |
Nursing
September 2008
Susan Simmons Holcomb |
Acute Abdomen: What a Pain! So many things - some life-threatening - can cause abdominal pain. Here's how to capture the clues quickly and accurately. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
